Director, Global Regulatory Affairs, Greater China and Intercontinental Policy Lead
Andrew Deavin has spent over 25 years in Regulatory Affairs operating in the UK, Europe and International, after having gained a M.Sc. and Ph.D. in Immunology. He has managed regulatory projects in development, registration and life-cycle primarily in vaccines but also in haematology/oncology. After 10 years in European Regulatory Affairs, Andrew focussed on International, particularly China and Asia Pacific for vaccine products, working on strategy and issue resolution before his current role in regional regulatory policy covering all product areas. Andrew works externally to reduce complexity in the regulatory environment and enhance access to innovative products. This includes active involvement in various industry associations. He leads the EFPIA ‘Korea & Taiwan’ regulatory network, is an active member of EFPIA’s China regulatory network and International Regulatory Expert Group (IREG) and works across EFPIA and IFPMA in post-approval changes (PACs). Most recently this has led to cross-industry position paper and publication in a peer-reviewed journal on PACs. Andrew has also presented on various regulatory topics in Asia and other locations during conferences over the years. Andrew now covers Regulatory Policy for GSK products in Greater China and Intercontinental region (which includes China, Japan, Korea and Canada). Andrew is currently based in Belgium.